Skip to content
Search

Latest Stories

CVS Health halts sale of phenylephrine cold and cough products

The panel of advisors pulled the OTC medicine from the shelves due to its ineffectiveness in unblocking stuffy nose

The American healthcare company, CVS Health, has decided to remove the cold and cough pills containing phenylephrine from the drug stores.


The following decision comes after the health regulator, the US Food and Drug Administration (FDA) determines the decongestant is ineffective towards flu if taken orally.

However, when ingested in pill or tablet form, this ingredient fails to reach its destination from the stomach to the nasal passages.

CVS Health spokesperson told USA Today, "We are removing a small number of oral decongestant products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores but will continue offering many other oral cough and cold products to meet consumer needs.”

They almost run more than 9,000 stores in the US whereas their rival, Walgreens has not yet taken the step to remove over-the-counter medications from their shelves.

iStock 1013348316 Phenylephrine is a common ingredient found in Benadryl, Kenvue's Tylenol, Haleon's Advil, Sudafed, and Dayquil. Credit: iStock

A Walgreens spokeswoman mentioned that the company is closely monitoring the situation and collaborating with its clinical integrity office and suppliers "on appropriate next steps."

Phenylephrine is a common ingredient found in several prominent cough and cold syrups sold in the U.S., including Benadryl, Kenvue's Tylenol, Haleon's Advil, Sudafed, and Dayquil.

This shift occurred primarily after a 2006 law restricted access to pseudoephedrine, a substance that can be used in the production of methamphetamine.

However, Dayquil will continue to be available at CVS stores because it contains a combination of active ingredients.

This ensures that these trusted medications remain accessible to customers.

The experts said some potential benefits of removing the ingredient include "lowering of overall healthcare costs, and avoiding missed opportunities for use of more effective treatments" like going to the doctor.

Dr Alison Cave, chief officer of MHRA commented on the usage of medicines containing phenylephrine, she said: “There have been no new safety concerns identified with phenylephrine-containing products and people can continue to use as directed.

“If you have any concerns about a medicine you are taking, please seek advice from a healthcare professional.”

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less